✦ LIBER ✦

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

✍ Scribed by K. Jordan; A. Hinke; A. Grothey; W. Voigt; D. Arnold; H.-H. Wolf; H.-J. Schmoll

Book ID: 106173756
Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 330 KB
Volume: 15
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-006-0186-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chemotherapy-induced emesis

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3receptor antagonists

✍ P. J. Hesketh 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 730 KB

Paul J. Hesketh the optimal use of the 5-HT3 antagonists and their integration into clinical practice remain unanswered and are the appropriate focus for additional study.

Consensus proposal for 5HT3antagonists i

Consensus proposal for 5HT3antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy

✍ D. R. Gandara; Fausto Roila; David Warr; Martin J. Edelman; Edith A. Perez; Rich 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 43 KB

A randomized, multicenter study comparin

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

✍ Bengt G. Sorbe; Thomas Högberg; Bengt Glimelius; Margareta Schmidt; Lars Wernste 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 900 KB

5-hydroxytryptamine type-3 receptor anta

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis : Can we safely reduce the dose of administered agents?

✍ Matti Aapro; Peter Blower 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Supported by Roche Laboratories. Dr. Blower has acted as a consultant to Glaxo-SmithKline, Novartis Pharma, and Hoffman-La Roche Laboratories and is a stockholder for Glaxo-SmithKline. Dr. Aapro has acted as a consultant for Roche Laboratories, Helsinn, Novartis Pharma, and Aventis, all of which a

Efficacy of an Ondansetron Orally Disint

Efficacy of an Ondansetron Orally Disintegrating Tablet: A Novel Oral Formulation of this 5-HT3 Receptor Antagonist in the Treatment of Fractionated Radiotherapy-Induced Nausea and Emesis

✍ J.P. LeBourgeois; C.J. McKenna; B. Coster; P. Feyer; L. Franzén; L. Goedhals; Z. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 140 KB

GR38032F, a 5HT3receptor antagonist, in

GR38032F, a 5HT3receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

✍ Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 330 KB

A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as